

Prescriber's Quick
Reference Guide

**Biosimilar Alternatives
for Commonly
Prescribed Biologics**



**superior
healthplan**™

List of Biosimilar Alternatives for Biological Reference

AVASTIN® (BEVACIZUMAB)

Biosimilar Alternative

Mvasi
(bevacizumab-awwb)

Manufacturer

Amgen Inc.

Biosimilar Alternative

Zirabev
(bevacizumab-bvzr)

Manufacturer

Pfizer Inc.

ENBREL® (ETANERCEPT)

Biosimilar Alternative

Eticovo
(etanercept-ykro)*

Manufacturer

Samsung Bioepis Co.,
Ltd.

Biosimilar Alternative

Erelzi
(etanercept-szsz)*

Manufacturer

Sandoz Inc..

HERCEPTIN® (TRASTUZUMAB)

Biosimilar Alternative

Herzuma
(trastuzumab-pkrb)

Manufacturer

CELLTRION, Inc.

Biosimilar Alternative

Ontruzant
(trastuzumab-dttb)*

Manufacturer

Samsung Bioepis Co.,
Ltd. and Merck Sharp &
Dohme Corp., Samsung
Bioepis Co., Ltd.

Biosimilar Alternative

Kanjinti
(trastuzumab-anns)

Manufacturer

Amgen Inc.

Biosimilar Alternative

Trazimera
(trastuzumab-qyyp)

Manufacturer

Pfizer Ireland
Pharmaceuticals

Biosimilar Alternative

Ogivri
(trastuzumab-dkst)

Manufacturer

Mylan GmbH, Mylan Gm

HUMIRA® (ADALIMUMAB)

Biosimilar Alternative

Abrilada
(adalimumab-afzb)+

Manufacturer

Pfizer Inc.

Biosimilar Alternative

Amjevita
(adalimumab -atto)+

Manufacturer

Amgen Inc.

Biosimilar Alternative

Cyltezo
(adalimumab-adbm)+

Manufacturer

Boehringer Ingelheim
Pharmaceuticals, Inc.

Biosimilar Alternative

Hadlima
(adalimumab-bwwd)+

Manufacturer

Samsung Bioepis Co., Ltd.
and Merck Sharp &
Dohme Corp., Samsung
Bioepis Co., Ltd.

Biosimilar Alternative

Hyrimoz
(adalimumab-adaz)+

Manufacturer

Sandoz Inc.

NEULASTA® (PEGFILGRASTIM)

Biosimilar Alternative

Fulphila
(pegfilgrastim-jmdb)

Manufacturer

Mylan GmbH

Biosimilar Alternative

Udenyca
(pegfilgrastim-cbqv)

Manufacturer

Coherus BioSciences, Inc.

Biosimilar Alternative

Ziextenzo
(pegfilgrastim-bmez)

Manufacturer

Sandoz Inc.

ARANESP® (DARBEPOETIN ALFA), EPOGEN® (EPOETIN ALFA), PROCRI® (EPOETIN ALFA)

Biosimilar Alternative

Retacrit
(epoetin alfa-epbx)

Manufacturer

Pfizer, Inc.

NEUPOGEN® (FILGRASTIM)

Biosimilar Alternative

Nivestym
(filgrastim-aafi)

Manufacturer

Pfizer Inc.

Biosimilar Alternative

Zarxio
(filgrastim-sndz)

Manufacturer

Sandoz Inc.

REMICADE® (INFLIXIMAB)

Biosimilar Alternative

Avsola
(infliximab-axxq)*

Manufacturer

Amgen Inc.

Biosimilar Alternative

Ixifi (infliximab-qbtX)*

Manufacturer

Pfizer Ireland
Pharmaceuticals

Biosimilar Alternative

Inflectra
(infliximab-dyyb)

Manufacturer

CELLTRION, Inc.

Biosimilar Alternative

Renflexis
(infliximab-abda)

Manufacturer

Samsung Bioepis Co.,
Ltd. and Merck Sharp &
Dohme Corp., Samsung
Bioepis Co., Ltd.

RITUXAN® (RITUXIMAB)

Biosimilar Alternative

Ruxience
(rituximab-pvvr)

Manufacturer

Pfizer Ireland
Pharmaceuticals

Biosimilar Alternative

Truxima
(rituximab-abbs)

Manufacturer

CELLTRION, Inc.

PLEASE NOTE:

Listed products are subject to change as
drug availability updates within the market.

+Product pending launch 2023

* Product pending launch date

Centene Corporation is a diversified, multi-national healthcare enterprise providing a comprehensive portfolio of innovative services including healthcare coverage for Medicaid, Medicare and the Health Insurance Marketplace. Centene also contracts with other healthcare and commercial organizations to provide specialty services for improved healthcare outcomes. We align the foundation of our purpose, transforming the health of the community, through enhancing patient health outcomes and lowering healthcare costs.

As healthcare expenditures rise, biosimilar drugs represent a clear opportunity to reduce healthcare costs while maintaining patient access to vital therapies. We request providers advocate for the use of biosimilar agents to align with the foundation of our purpose.

Biosimilars



SAFE AND EFFECTIVE

Biosimilars are FDA-approved, safe and effective medicines that are highly similar to existing biologic medicines.¹

The FDA regulates biosimilar manufacturing to ensure they scientifically demonstrate safety and effectiveness while showing no clinically meaningful differences.¹



INCREASE PATIENT ACCESS

Biosimilar adoption increases access and treatment options for patients as additional agents continue to enter the market.



COST SAVING

With increased availability, healthcare providers can potentially purchase these medicines at wholesale cost.

¹ US Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity. URL: <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/scientific-considerations-demonstrating-biosimilarity-reference-product>